Phylogica rings in 2012 with fourth major pharma alliance
This article was originally published in Scrip
Executive Summary
2012 has got off to a good start for the Australian peptide firm Phylogica, which is to use its proprietary platform technology to discover novel drugs for the Janssen Biotech arm of Johnson & Johnson in what is its broadest alliance to date.